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Short bowel syndrome (SBS) is defined as an intes-tinal failure following a loss of intestinal length that causes marked maldigestion and malabsorption of 
dietary nutrients and induces major fecal loss of energy, 
nitrogen, and fat.1 SBS is a common problem in pediatric 
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surgery and occurs in newborns and infants suffering 
from necrotizing enterocolitis, intestinal atresia, and vol-
vulus that require massive intestinal resection.2 Despite 
advances in resuscitation, the availability of parenteral 
nutrition (PN) and potent antibiotics, and modern tech-
niques of organ support, SBS remains a significant cause 
of infant morbidity and mortality.2
The survival of patients after massive small bowel 
resection depends on the ability of the residual bowel to 
adapt. Adaptation is the term applied to progressive recov-
ery from intestinal failure following a loss of intestinal 
length.3,4 The remaining intestine dilates, elongates, and 
thickens; villous height and crypt depth increase, leading 
to mucosal hyperplasia and increasing the absorptive sur-
face area (structural adaptation). In addition, increased 
nutrient absorption by isolated enterocytes occurs (func-
tional absorption). Over the past decades, much research 
has focused on determining which factors promote intes-
tinal regrowth.
Background: The purpose of the present study was to evaluate 
the effects of ω-3 fatty acids (Omegaven) on early intestinal 
adaptation in rats with short bowel syndrome (SBS). Methods: 
Male Sprague-Dawley rats were randomly assigned to 1 of 4 
groups: sham rats underwent bowel transection; SBS rats under-
went 75% bowel resection; SBS-O ω-3 rats underwent bowel 
resection and were treated with oral Omegaven given by gavage; 
and SBS-I ω-3 rats underwent bowel resection and were treated 
with Omegaven given intraperitoneally. Rats were killed on day 
14. Parameters of intestinal adaptation (bowel and mucosal 
weight, mucosal DNA and protein, villus height and crypt 
depths, cell proliferation and apoptosis) were determined at time 
of death. Real-time polymerase chain reaction was used to deter-
mine the level of Bax and Bcl-2 messenger RNA (mRNA). 
Statistical analysis was performed using Kruskal-Wallis test 
followed by post hoc test, with P < .05 considered statistically 
significant. Results: Oral ω-3 supplementation did not signifi-
cantly change intestinal regrowth. In contrast, parenteral ω-3 in 
rats that underwent resection resulted in  higher bowel and 
mucosal weights, mucosal DNA and protein in ileum, villus 
height in ileum, crypt depth in jejunum and ileum, and greater 
rates of cell proliferation in jejunum and ileum compared with 
SBS animals. The initial decreased levels of apoptosis corre-
sponded with the early decrease in Bax and increase in Bcl-2 
mRNA levels. Conclusions: Parenteral but not enteral Omegaven 
augments and accelerates structural bowel adaptation in a rat 
model of SBS. Increased cell proliferation and decreased apopto-
sis reflect increased cell turnover in Omegaven-treated animals. 
(JPEN J Parenter Enteral Nutr. 2010;34:503-512)
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Enteral feeding is one of the major trophic factors in 
stimulating intestinal adaptation.5 However, not all nutri-
ents have equal stimulating trophic effects. Although tra-
ditional dietary management advocates a restricted-fat 
diet containing 50% to 75% medium-chain triglycerides as 
a source of fat, there are still questions concerning the 
relative value of high-fat vs high-carbohydrate diets for 
these patients. Among the factors promoting postresec-
tion intestinal adaptation, long-chain fatty acids (FAs) are 
considered the most effective.1,5 Several experimental 
studies have demonstrated that bowel regrowth can be 
altered by changing dietary ratios of different FAs. It has 
been reported that animals with SBS receiving a diet defi-
cient in essential FAs have significantly impaired intesti-
nal mucosal hyperplasia.6 The FA arachidonic acid appears 
to be a potent stimulator of intestinal adaptation, more 
than its precursor, linoleic acid.7 However, dietary linoleic 
acid has higher stimulating effects on postresection 
mucosal hypertrophy compared with palmitic acid.8 We 
have recently shown that restriction of palmitic acid in the 
diet inhibits intestinal adaptation and that a diet high in 
palmitic acid has a mildly stimulating effect on intestinal 
regrowth.9
Over the past years, several preliminary clinical trials 
have described the positive effects of ω-3 FA fish oil–
based lipid (Omegaven; Fresenius Kabi, Bad Homburg, 
Germany) in prevention of PN-associated liver disease 
(PNALD) in children with SBS. In a recent review, 
Diamond et al10 discussed the rationale for the use of 
ω-3 FAs. The authors noted that the beneficial effects of 
substituting ω-6 FAs with ω-3 FAs are likely related to 3 
major mechanisms: (1) the addition of ω-3 FAs improves 
bile flow; (2) ω-3 FAs decrease steatosis; and (3) the addi-
tion of ω-3 FAs shifts the eicosanoid profile toward a less 
inflammatory state. Together, these actions result in 
decreased cholestasis, hepatitis, and subsequent fibro-
sis.10 Because liver disease may hinder intestinal adapta-
tion,11 ω-3 FAs may ultimately facilitate adaptation in 
these children by treating their liver disease.
The purpose of the present study was to evaluate the 
effects of Omegaven on structural intestinal adaptation in 
a rat model of SBS.
Methods
Animals
The Rappaport Faculty of Medicine (Technion, Haifa, 
Israel) Institutional Animal Care and Use Committee 
approved the animal facilities and protocols. Briefly, male 
rats weighing between 240 and 260 g were kept in indi-
vidual stainless steel cages at constant temperature and 
humidity, and a 12-hour light–dark cycle was maintained. 
Rats were fasted 12 hours before the experiment with free 
access to water.
Experimental Design
Because intraperitoneal injection of FAs may cause an 
inflammatory response, a pilot study was performed in 
normal (nonoperated) rats that were given either 
intraperitoneal or oral Omegaven. After 7 days of 
treatment, the rats were killed. Blood samples (1 mL) 
were obtained from the left ventricle (peripheral 
blood). Cholesterol and triglyceride levels in serum 
were measured at time of death using standard enzy-
matic methods (Cobas Integra 700 Analyzer; Roche, 
Holliston, MA). The peritoneum and intestinal walls 
were examined for macroscopic and microscopic signs 
of inflammation.
Forty rats were randomly assigned to 1 of 4 groups. In 
group A (n = 10), sham rats underwent bowel transection; 
in group B, the SBS group (n = 10), animals underwent 
bowel resection; in group C, the SBS-O ω-3 group (n = 
10), rats underwent bowel resection and were treated 
with 1 mL/d oral Omegaven given by gavage in group D, 
the SBS-I ω-3 group (n = 10), rats underwent bowel 
resection and were treated with 1 mL/d intraperitoneal 
Omegaven. The dose of Omegaven was chosen in accord-
ance with previously described studies.12 The use of intra-
peritoneal PN in animal models is well-known and was 
summarized by LeLeiko,13 who concluded that intraperi-
toneal PN provides a relatively simple and efficient 
method of studying PN in laboratory animals.
Rats were pair-fed and followed for 14 days with moni-
toring of food and fluid intake and weight measurement.
Surgical Procedure
After a 12-hour fast, animals were anesthetized with 
intraperitoneal ketamine (90 mg/kg) and xylasine (10 
mg/kg). The abdomen was opened using a midline inci-
sion with sterile techniques. A sham operation was 
performed by simple transection of the ileum 15 cm 
proximal to the ileocecal junction and reanastomosis. 
Resected animals underwent 75% small bowel resec-
tion from 5 cm distal to the ligament of Treitz to 10 cm 
proximal to the ileocecal valve. Mesenteric vessels were 
ligated with 5-0 silk sutures, and bowel continuity was 
restored by end-to-end anastomosis using 5-0 Dexon 
(Davis & Geck, NY) interrupted sutures. For all opera-
tions, the abdominal cavity was closed in 2 layers with 
a running suture of 3-0 Dexon (Davis & Geck). Before 
closure of the abdomen, the rats were resuscitated with 
a 3-mL intraperitoneal injection of warm normal saline. 
Rats were fasted for 24 hours but were allowed free 
access to water.
Parameters of Intestinal Adaptation
On postoperative day 15, the animals were killed after 
intraperitoneal injection of pentobarbital (75 mg/kg). The 
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small intestine from the pylorus to the ileocecal valve was 
removed and divided into 2 segments: the jejunum proxi-
mal to anastomosis and the terminal ileum. Equivalent 
lengths of intestine from sham-operated animals were 
obtained from the corresponding areas. Portions of intes-
tine located 1 cm to either side of anastomosis were dis-
carded. Each segment was weighed and cut longitudinally. 
Mucosa was scraped using a spatula, collected, and 
weighed. Bowel and mucosal weights were calculated per 
cm of bowel length per 100 g of body weight, as described 
previously.14,15 DNA and protein were extracted using 
TRIzol Reagent (Invitrogen) as described by Chomczynski.16 
The DNA concentrations were recorded spectrophoto-
metrically and calculated per cm of bowel length per 100 g 
of body weight. Final protein concentration was measured 
spectrophotometrically using a commercially available kit 
(Bio-Rad Protein Assay, Bio-Rad Laboratories Ltd, Rishon 
Le Zion, Israel) and was calculated per cm of bowel length 
per 100 g of body weight.
Histological Examination
Intestinal samples from the proximal jejunum and distal 
ileum were fixed in 10% formalin, dehydrated in progres-
sive concentrations of ethanol, cleared in xylene, and 
embedded in paraffin wax. Deparaffinized 5-mcm sec-
tions were stained with hematoxylin and eosin. These 
sections were studied microscopically using a micrometer 
eyepiece. Histologic images were loaded on a 760×570-
pixel resolution buffer using a computerized image analy-
sis system composed of a trichip RGB video camera 
(Sony, Japan) installed on a light microscope (Zeiss, 
Germany) and attached to an IBM-compatible personal 
computer equipped with a frame grabber. Images were 
captured, digitized, and displayed on a 17-inch, high-
resolution color monitor. The villus height and crypt 
depth were measured using Image Pro Plus 4 image 
analysis software (Media Cybernetics, Baltimore, MD). 
Ten villi and crypts in each section were measured, and 
the mean reading was recorded in mcm.
Enterocyte proliferation and apoptosis. Standard 5-bromo-
deoxyuridine (5-BrdU) labeling reagent (Zymed Laborato-
ries, San Francisco, CA) was injected intraperitoneally at 
a concentration of 1 mL per 100 g of body weight 2 hours 
before animals were killed. Crypt cell proliferation was 
assessed using a biotinylated monoclonal anti-BrdU anti-
body system provided in a kit (Zymed Laboratories). 
Briefly, 5-mcm sections were cut from paraffin-embedded 
blocks. For antigen retrieval, sections were microwave 
treated in preheated 0.01 molar citrate buffer (pH 6.0) for 
10 minutes. Sections were then pretreated with denatur-
ing solution for 20 minutes and blocked with horse serum 
for 10 minutes to block nonspecific binding before incu-
bation with the primary antibody. The slides were stained 
with a biotinylated monoclonal anti-BrdU antibody for 
60 minutes at room temperature. Then the slides were 
treated with streptavidin peroxidase for 10 minutes. 
BrdU-positive color development was obtained by incu-
bating the sections with diaminobenzidine (DAB) mixture 
for 3 to 5 minutes. An index of proliferation was deter-
mined as the ratio of crypt cells staining positively for 
BrdU per 10 crypts.
Additional 5-mcm thick sections were prepared to 
establish the degree of enterocyte apoptosis. Immunohis-
tochemistry for caspase 3 was performed to identify 
apoptotic cells using a combination of streptavidin– 
biotin–peroxidase method and microwave antigen retrieval 
on formalin-fixed, paraffin-embedded tissues according to 
the manufacturers’ protocols. Briefly, the sections were 
deparaffinized, rehydrated in graded alcohol, and micro-
wave pretreated in ethylenediaminetetraacetic acid buffer 
for 10 minutes. Then the specimens were incubated in 
peroxidase quenching solution (3% H2O2 in methanol) for 
10 minutes and blocked with serum-blocking solution for 
10 minutes. Thereafter, samples were stained with pri-
mary cleaved caspase-3 polyclonal antibodies (diluted 
1:100; Biocare Medical, Walnut Creek, CA) for 60 min-
utes in a moist chamber at room temperature. After the 
primary antibody was washed off with phosphate- 
buffered saline, slides were incubated with a secondary 
human-absorbed, biotinylated, affinity-purified antibody. 
Enhanced horseradish peroxidase–conjugated streptavi-
din was subsequently applied at room temperature for 10 
minutes before the sections were visualized with DAB to 
create an intense brown deposit around the antigen–
antibody–enzyme complex in the sample. The apoptotic 
index was defined as the number of apoptotic cells per 10 
villi. Assessment was performed in a blinded manner by a 
qualified pathologist.
Real-time PCR. Expression of Bax and Bcl-2 levels was 
determined by quantitative real-time polymerase chain 
reaction (PCR) (7500 Real-Time PCR System–Applied 
Biosystems, Foster City, CA) on complementary DNA 
(cDNA) samples using SYBR Green Master Mix (Rovalab, 
Teltow, Germany) with the exception of template and 
primers. Primers for Rattus norvegicus Bax and Bcl-2 were 
synthesized by Syntezza Bioscience (Jerusalem, Israel), 
and 18s ribosomal RNA with a 260:280 nm ratio of absor-
bance was purchased as a control kit from Eurogentec, 
EGT Group (Israel). Total RNA was isolated using TRIzol 
according to the manufacturer’s instructions. The amount 
of total RNA was measured by spectrophotometry (Thermo 
Scientific NanoDrop 1000). Two mcg RNA were reverse-
transcribed to cDNA at 37°C using a reverse transcription 
kit (AffinityScript; Stratagene, Ornat, Israel). The follow-
ing thermal cycler (T3 Thermocycler; Biometra, Tamar, 
Israel) settings were used: 94°C for 5 minutes followed by 
30 cycles of 94°C × 15 seconds, 55°C × 15 seconds, and 
72°C × 30 seconds, followed by a 7-minute extension at 
72°C. Thermal cycler settings were optimized to ensure 
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that products were in the linear phase of production. 
Amplification was followed by a melting curve analysis to 
confirm PCR product. No signals were detected in no-
template controls. The experimental threshold was calcu-
lated using the algorithm enhancements provided by 7500 
System SDS version 1.2.3 software (Applied Biosystems). 
All samples were run in duplicate, and the mean value of 
each duplicate was used for all further calculations.
Statistical Analysis
The data are expressed as the mean ± standard error of 
the mean. Statistical analysis of parameters of adaptation, 
enterocyte proliferation, and apoptosis was performed 
using Kruskal-Wallis test followed by post hoc test for 
multiple comparisons. A P value < .05 was considered 
statistically significant.
Results
Effects of Omegaven on Abdominal Cavity  
and Plasma Lipids in Normal Rat
In normal, nonoperated rats, neither oral nor intra-
peritoneal Omegaven caused an inflammatory response 
(macroscopic and microscopic) within the peritoneal cavity 
and intestinal wall. Treatment with intraperitoneal Omegaven 
did not change cholesterol levels but significantly 
increased triglyceride levels (67 ± 2 vs 42 ± 4 mg/dL, P < 
.05). Administration of oral Omegaven resulted in a lower 
cholesterol level (91 ± 4 vs 108 ± 7 mg/dL, P < .05) but 
did not change triglyceride levels compared with non-
treated animals.
Body Weight
The body weight of sham-operated control rats remained 
unchanged during the first 4 days, followed by a gradual 
increase in weight throughout the next 10-day observa-
tion period (Figure 1). The bowel resection group (group 
B) experienced a significant reduction in weight during 
the first 4 days, followed by a gradual increase in weight 
during the next 10 days. However, final body weight was 
significantly lower in SBS rats compared with sham ani-
mals. Administration of enteral ω-3 did not significantly 
change weight gain compared with SBS untreated ani-
mals. Nevertheless, treatment with parenteral Omegaven 
resulted in a greater weight gain compared with the 2 
other groups that underwent resection.
Intestinal Mucosal Parameters
Compared with sham animals (group A), a 75% proximal 
small bowel resection (group B) resulted in a significant 
increase in bowel weight in the jejunum (5-fold increase, 
P < .05) and ileum (2-fold increase, P < .05); mucosal 
weight in the jejunum (5-fold increase, P < .05) and ileum 
(2-fold increase, P < .05) (Figure 2); mucosal DNA in the 
jejunum (3-fold increase, P < .05); and ileum (3-fold 
increase, P < .05); and mucosal protein in the jejunum 
(8-fold increase, P < .05) and ileum (3-fold increase, 
P < .05) (Figure 3). Resected animals receiving enteral ω-3 
had similar bowel and mucosal weight in jejunum and ileum 
(Figure 3), mucosal DNA in jejunum and ileum, and muco-
sal protein in jejunum compared with SBS counterparts 
(group B, Figure 3). Only ileal protein content was increased 
in this group compared with SBS animals. Compared with 
SBS animals (group B), treatment with parenteral ω-3 
(group D) significantly increased jejunal (24%, P < .05) and 
ileal (35%, P < .05) bowel weight; ileal (39%, P < .05) muco-
sal weight; ileal (50%, P < .05) mucosal DNA content; and 
jejunal (49%, P < .05) and ileal mucosal protein content 
(3-fold increase, P < .05).
Histological Findings
Data for histological changes in remaining bowel are 
shown in Figure 4. As expected, small bowel resection 
(group B) markedly increased villus height in the jejunum 
(33%, P < .05) and ileum (34%, P < .05) and crypt depth 
in the jejunum (31%, P < .05) compared with sham ani-
mals (group A). Treatment with enteral ω-3 (group C) did 
not significantly change villus height and crypt depth 
compared with SBS untreated animals (group B). 
Treatment with parenteral Omegaven led to a significant 
 
Figure 1.  Effect of bowel resection and Omegaven on the 
body weight changes. Values are mean ± standard error of the 
mean. SBS, short bowel syndrome; Oω3, oral ω-3; Iω3, intra-
peritoneal ω-3. Administration of enteral ω-3 did not signifi-
cantly change body weight gain compared with SBS untreated 
animals. Treatment with parenteral Omegaven resulted in 
greater weight gain compared with the other 2 resected groups. 
*P < .05 SBS vs sham rats; §P < .05 SBS-Oω3 vs SBS-Iω3 rats.
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increase in villus height in the ileum (30%, P < .05) and 
crypt depth in jejunum (21%, P < .05) and ileum (24%,
P < .05) compared with SBS animals (group A).
Cell Proliferation and Apoptosis
A significant increase in cell proliferation was seen in 
rats that underwent resection (group B) compared with 
sham animals (group A) in both jejunum (264 ± 17 vs 
211 ± 17 BrdU-positive cells per 10 crypts, P < .05) and 
ileum (261 ± 15 vs 192 ± 19 BrdU-positive cells per 10 
crypts, P < .05) (Figure 5). Following oral Omegaven 
supplementation, SBS rats (group C) demonstrated a 
mild to significant decrease in jejunal (232 ± 8 vs 264 ± 
17 BrdU-positive cells per 10 crypts, P < .05) proliferation 
rates compared with SBS untreated animals (group B) 
and a trend toward decreased cell proliferation in the 
ileum; however, this trend was not statistically significant. 
In contrast, treatment with parenteral ω-3 (group D) 
significantly increased jejunal (304 ± 11 BrdU-positive 
cells per 10 crypts, P < .05) and ileal (307 ± 17 BrdU-positive 
cells per 10 crypts, P < .05) proliferation rates compared 
with the other 3 groups.
SBS rats (group B) demonstrated a significant 
increase in cell apoptosis in jejunum (2.0 ± 0.06 vs 
0.60 ± 0.21 apoptotic cells per 5 villi, P < .05) and ileum 
(3.66 ± 0.80 vs 1.31 ± 0.50 apoptotic cells per 5 villi, P < 
.05) compared with sham animals (Figure 6). Following 
enteral and parenteral ω-3 supplementation, SBS rats 
(groups C and D) showed a significant decrease in cell 
apoptosis in jejunum (0.75 ± 0.24 and 1.08 ± 0.32 vs 2.0 
± 0.06 apoptotic cells per 5 villi, P < .05, respectively) 
and ileum (1.55 ± 0.40 and 2.07 ± 0.28 vs 3.66 ± 0.80 
apoptotic cells per 5 villi, P < .05, respectively) compared 
with SBS untreated animals.
Expression of Bax and Bcl-2 Genes
An elevated rate of apoptosis in SBS rats (group B) was 
accompanied by a 3-fold increase in Bax messenger RNA 
(mRNA) expression (P < .05) and no change in Bcl-2 
mRNA expression compared with control animals (group 
A, Figure 7). Treatment with oral ω-3 (group C) attenu-
ated the proapoptotic effects of bowel resection. SBS-O 
ω-3 rats showed a significant decrease in Bax expression 
(4-fold decrease, P < .05) and a 3-fold increase in a Bcl-2 
mRNA expression compared with SBS animals. Parenteral 
administration of ω-3 (group D) resulted in a more sig-
nificant decrease in Bax mRNA expression (12-fold 
decrease, P < .05) and a similar oral ω-3 increase in Bcl-2 
mRNA levels (3-fold increase, P < .05) compared with 
SBS animals.
Discussion
The ability to absorb many nutrients is decreased follow-
ing massive bowel resection, and lipid absorption is gen-
erally considered the most vulnerable function.17,18 The 
combined loss of absorptive surface area and compro-
mised enterohepatic circulation,19 decreased bile acid 
pool,20,21 and decreased pancreatic lipase secretion22 
result in steatorrhea and inefficient fat absorption. 
Therefore, patients with SBS are often given elemental 
diets containing medium-chain lipids during the early 
stages of enteral feeding. However, increasing evidence 
suggests that long-chain fats are more effective stimula-
tors of intestinal adaptation than either medium-chain 
fats or carbohydrates.17 Therefore, several investigators 
have recommended adding long-chain FAs to the diets of 
patients with SBS.1
Although the positive effects of FAs in stimulating 
small intestinal adaptation have been reported over the 
years in many preclinical and clinical investigations,5-9 
 
Figure 2.  Effect of bowel resection and ω-3 fatty acid supple-
mentation on the macroscopic appearance of the remaining 
small intestine. SBS, short bowel syndrome; Oω3, oral ω-3; Iω3, 
intraperitoneal ω-3. Massive small bowel resection significantly 
increased bowel and mucosal weight in jejunum and ileum com-
pared with sham animals that did not undergo resection. 
Resected animals receiving enteral ω-3 had similar bowel and 
mucosal weight in jejunum and ileum compared with SBS ani-
mals. Treatment with parenteral ω-3 (group D) significantly 
increased jejunal and ileal bowel weight as well as ileal mucosal 
weight compared with SBS animals. Values are mean ± standard 
error of the mean. *P < .05 SBS vs sham rats; †P < .05 SBS-
Oω3 and SBS-Iω3 vs SBS rats; §P < .05 SBS-Oω3 vs SBS-Iω3 
rats.
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other studies have yielded conflicting conclusions regard-
ing the benefits of ω-3 FAs in SBS.10,23 Intravenous lipids 
are a critical component of PN solutions because they 
provide essential FAs and dense calories. However, fat 
emulsions have also been implicated as a significant cause 
of PNALD.10,11 The main long-chain polyunsaturated FAs 
in PN solutions are ω-6 FAs and ω-3 FAs. ω-6 FAs and 
ω-3 FAs share metabolic pathways and thus interact with 
each other through a complex system involving dietary 
substrate availability, competition for the same metabolic 
enzymes for synthesis and membrane incorporation, and 
powerful negative feedback of the end products.24 There 
is emerging evidence that ω-6 FAs may play a major role 
in the development of PNALD and that ω-3 FAs may 
ameliorate this effect by improving bile flow, inhibiting 
steatosis, and conferring immunomodulatory effects.10 
Gura and co-workers23 recently reported the reversal of 
cholestasis in 2 infants with intestinal failure and PNALD 
after treatment with conventional intravenous fat emulsion, 
with 1 containing primarily ω-3 FAs. 
Because liver disease may hinder intestinal adaptation,11 
we hypothesized that ω-3 FAs may ultimately stimulate 
intestinal adaptation in patients with SBS by treating 
their liver disease. In addition, ω-3 FAs may exert a direct 
stimulating effect on intestinal regrowth by increasing 
proliferation and decreasing apoptosis of crypt cells. The 
purpose of the present study was to evaluate the effects 
of enteral and parenteral ω-3 on structural intestinal 
adaptation following massive small bowel resection in 
rats. In a previous study, transperitoneal absorption of a 
commercial fat emulsion (Liposyn 10%; Abbott Laboratories, 
Chicago, IL) was studied in 12 beagle puppies.25 In this 
experiment, serum triglycerides had increased 3-fold 
within 15 minutes after intraperitoneal fat injection and 
then decreased slowly, although remaining significantly 
elevated at 4 hours. Animals receiving no intraperitoneal 
fat showed no change in serum triglycerides. The authors 
concluded that a fat emulsion can be quantitatively 
absorbed from the peritoneal cavity over 4 hours and that 
intraperitoneal nutrition may be feasible.
In the current study, changes in bowel and mucosal 
weights, mucosal DNA and protein content, and 
histological appearance were measured to characterize 
intestinal adaptation. In addition, cell proliferation and 
apoptosis were measured to investigate enterocyte turno-
ver. Two differentiation modulators of apoptosis (Bax and 
Bcl-2) were determined in tissue samples and quantified 
at mRNA levels relative to control levels. In the normal 
 
Figure 3.  Effect of bowel resection and treatment with ω-3 fatty acid on mucosal DNA and protein content. SBS, short bowel 
syndrome; Oω3, oral ω-3; Iω3, intraperitoneal ω-3. SBS rats demonstrated a significant increase in mucosal DNA and protein in 
jejunum and ileum compared with sham animals. Whereas treatment with oral Omegaven significantly increased ileal protein con-
tent, parenteral Omegaven significantly increased ileal mucosal DNA content and jejunal and ileal mucosal protein content com-
pared with SBS animals. Values are mean ± standard error of the mean. *P < .05 SBS vs sham rats; †P < .05 SBS-Oω3 and SBS-Iω3 
vs SBS rats.
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physiologic state, the production of crypt cells and loss of 
cells at the villus tip are balanced to maintain the normal 
mass of gut mucosa. Cell loss in the small intestine after 
bowel resection is mainly regulated by programmed cell 
death. The Bcl-2 family has been implicated in both 
positive and negative regulation of intestinal cell apopto-
sis. Augmented expression of Bcl-2 acts in situ on mito-
chondria to prevent the release of cytochrome c and thus 
caspase activation, whereas Bax localizes to mitochondria 
and induces the release of cytochrome c, activation of 
caspase 3, membrane blebbing, nuclear fragmentation, 
and cell death.26 It is generally accepted that the Bax to 
Bcl-2 ratio determines the cell’s fate, whereby excess 
Bcl-2 confers survival and excess Bax promotes cell 
death. In the gut, Bcl-2 is mostly expressed at the base of 
the colonic crypt but less in the small intestinal mucosa, 
whereas Bax is predominant in the crypts of the 
small intestine. The higher ratio of proapoptotic to antia-
poptotic genes in the small intestine (compared with in 
the large intestine) is most likely related to the large vol-
ume of potential toxins received by the small intestine, 
most of which have been neutralized before arrival in the 
colon.
Consistent with our previous experiments,14,15 our 
current findings showed that massive intestinal resection 
results in significant structural adaptation. This conclu-
sion is supported by the observed increase in bowel and 
mucosal weight of the remnant bowel, increase in mucosal 
DNA and protein, and increase in villus height and crypt 
depth in this model. Decrease in body weight in rats that 
underwent resection may suggest malnutrition despite 
the adaptation process. Parallel increases in mucosal 
DNA and protein indicate that the greater intestinal mass 
of resected animals can be attributed to cellular hyperpla-
sia. Because the DNA and protein content are directly 
proportional to mucosal cell number, these measure-
ments exclude such factors as edema and vascular 
engorgement as responsible for differences in mucosal 
mass. Most significant differences were observed in the 
terminal ileum, whereas hyperplasia in the proximal jeju-
num was less prominent. We used 5-BrdU to determine 
an index of crypt cell proliferation. This analogue of thy-
midine is incorporated into the DNA of proliferating cells 
during the S phase of the cell cycle. Our findings suggest 
that proliferation of crypt cells increased significantly fol-
lowing bowel resection and was closely correlated with 
increased crypt depth. The enhanced cell production was 
accompanied by an increased cell apoptosis, suggesting 
accelerated cell turnover. Increased cell apoptosis may be 
considered a mechanism that counterbalances the 
increased enterocyte proliferation in order to reach a new 
homeostatic set during intestinal adaptation. In addition, 
increased apoptosis promotes disposal of genetically aber-
rant stem cells and prevents tumorogenesis.27,28 The 
mucosal response to massive resection in our experiment 
is comparable to the changes previously observed in our 
laboratory.14,15 Bax mRNA expression was upregulated, 
whereas Bcl-2 mRNA did not change significantly during 
intestinal adaptation for a specific period. As a result, the 
Bax to Bcl-2 ratio increased in SBS rats, which correlates 
with the enhanced enterocyte apoptosis in this group.
The present study demonstrates that enteral ω-3 did 
not significantly change structural intestinal adaptation. 
This conclusion is supported by unchanged bowel and 
mucosal weights of the remnant bowel. In contrast, in 
several mucosal parameters, a trend toward an inhibitory 
effect was observed. A decrease in villus height in the 
jejunum suggests a decreased absorptive surface area in 
this group of animals. This experiment does not address 
whether impaired structure is associated with impaired 
function. However, decreased absorptive surface area is 
assumed to be accompanied by decreased nutrient absorp-
tion. Decrease in body weight in rats receiving oral 
Omegaven may suggest malnutrition. In parallel with 
these morphological changes, the epithelial cell turnover 
of the small intestine of PO-treated rats was significantly 
affected. We should emphasize that intestinal mucosal 
hypoplasia is a result of hypoproliferation in intestinal 
 
Figure 4.  Effect of bowel resection and treatment with 
Omegaven on the microscopic appearance of the remaining 
small intestine. SBS, short bowel syndrome; Oω3, oral ω-3; Iω3, 
intraperitoneal ω-3. Small bowel resection markedly increased 
villus height in jejunum and ileum and crypt depth in jejunum 
compared with sham animals. Treatment with enteral ω-3 did 
not significantly change villus height and crypt depth compared 
with SBS untreated animals. Treatment with parenteral 
Omegaven significantly increased villus height in ileum as well 
as crypt depth in jejunum and ileum compared with SBS ani-
mals. Values are mean ± standard error of the mean. *P < .05 
SBS vs sham rats; †P < .05 SBS-Oω3 and SBS-Iω3 vs SBS rats.
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crypts secondary to dietary treatment, which leads to 
villous atrophy and absorptive dysfunction. The mecha-
nism of the decrease in cell apoptosis is poorly under-
stood. The rate of cell death must be roughly equal to 
the rate of cell proliferation to maintain gut homeosta-
sis. Thus, either cell death or cell proliferation was 
inhibited by oral Omegaven administration. The oppo-
site factor then decreased in compensation. The alterna-
tive hypothesis is that both apoptosis and proliferation 
were inhibited by oral Omegaven. In this experiment, we 
could not assess which of these possibilities led to our 
findings. We found a mild decrease in Bax mRNA and 
increase in Bcl-2 mRNA levels of SBS rats treated with 
enteral Omegaven that correlated with decreased rates 
of cell apoptosis.
In the present study, administration of parenteral 
Omegaven in SBS rats significantly enhanced structural 
intestinal adaptation. Parenteral Omegaven significantly 
increased overall bowel and mucosal weights, which 
occurred with a synergistic increase in bowel circumference. 
Omegaven significantly increased ileal mucosal DNA and 
protein as well. Parallel increases in mucosal DNA and 
protein indicate that the greater ileal mass of animals 
treated with parenteral Omegaven can be attributed to 
cellular hyperplasia. Omegaven caused also a mild stimu-
lation of cell proliferation and concomitant decrease in 
cell apoptosis compared with SBS nontreated animals, 
suggesting an activated enterocyte turnover, which may 
be considered a main mechanism of mucosal hyperplasia 
in recovering bowel. Bax mRNA levels were downregu-
lated, whereas Bcl-2 mRNA was upregulated in Omegaven-
treated rats compared with SBS nontreated animals. In 
accord, the Bax to Bcl-2 ratio decreased in SBS-Iω3 rats 
compared with SBS animals, suggesting increased entero-
cyte survival.
The reason Omegaven has opposite effects depend-
ing on the route of administration is poorly understood. 
Omegaven is not intended for enteral administration, and 
we are aware of no previous investigations that tested 
enteral administration of Omegaven in both animal and 
 
Figure 5.  Effect of bowel resection and Omegaven on crypt 
cell proliferation. SBS, short bowel syndrome; Oω3, oral ω-3; 
Iω3, intraperitoneal ω-3; BrdU, bromodeoxyuridine. Incorpora-
tion of 5-BrdU into proliferating jejunal and ileal crypt cells was 
detected with a goat anti-BrdU antibody. A significant increase 
in cell proliferation was seen in SBS rats in jejunum and ileum 
compared with sham animals. Following oral Omegaven sup-
plementation, SBS rats demonstrated a mild but significant 
decrease in jejunal proliferation rates compared with SBS 
untreated animals. Treatment with parenteral ω-3 significantly 
increased jejunal and ileal proliferation rates compared with the 
other 3 groups. Values are mean ± standard error of the mean. 
*P < .05 SBS vs sham rats; †P < .05 SBS-Oω3 and SBS-Iω3 vs 
SBS rats; §P < .05 SBS-Oω3 vs SBS-Iω3 rats.
 
Figure 6.  Effect of bowel resection and treatment with ω-3 
fatty acids on enterocyte apoptosis in jejunum and ileum. SBS, 
short bowel syndrome; Oω-3, oral ω-3; Iω-3, intraperitoneal 
ω-3. Immunochemistry for caspase-3 was used to determine 
enterocyte apoptosis. SBS rats demonstrated a significant 
increase in cell apoptosis in jejunum and ileum compared with 
sham animals. Following enteral and parenteral ω-3 supplemen-
tation, SBS rats showed a significant decrease in cell apoptosis 
in jejunum and ileum compared with SBS untreated animals. 
Values are mean ± standard error of the mean. *P < .05 SBS vs 
sham rats; †P < .05 SBS-Oω-3 and SBS-Iω-3 vs SBS rats; §P < 
.05 SBS-Oω-3 vs SBS-Iω-3 rats.
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human models. The local exposure to Omegaven in the 
short bowel state with decreased absorption and faster 
transit time may negatively affect the bowel. This is fur-
ther supported by the fact that intraperitoneal but not 
enteral Omegaven administration in control (nonop-
erated) rats resulted in a significant increase in serum 
triglyceride levels. In the present study, ω-3 FAs exerted 
the major stimulating effects on intestinal regrowth by 
bypassing the gut.
We conclude that parenteral Omegaven enhances 
cell proliferation and inhibits programmed cell death 
through upregulation of Bcl-2 and downregulation of Bax 
expression in this rat model. Enteral Omegaven does 
not change intestinal regrowth. Parenteral Omegaven 
stimulates enterocyte turnover and may be clinically ben-
eficial as an agent to stimulate intestinal adaptation in 
patients with SBS.
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